Breast Implant Safety
Advice to patients regarding concerns over the safety of breast implants
Allergan implants are no longer being made available for use, and all stock left within hospitals has been recalled back to the manufacturer. Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is relatively rare and the regulatory authorities have suggested that implants that are currently in place should not be routinely removed as the risks of surgery outweigh the benefits at this time.
The current advice is that patients should be aware of the symptoms of BIA-ALCL -primarily persistent swelling or pain near the breast implants- and monitor the area around the breast implants for any changes.
If you experience any of these symptoms or other changes, please contact Mr Nduka who will be happy to speak to you to assess the need for further evaluation. Evaluation for BIA-ALCL typically involves a physical examination, imaging and/or assessment of the fluid or tissue around the breast implant. It is important to undergo an evaluation to diagnose BIA-ALCL since a confirmed BIA-ALCL diagnosis may change the type of operation that should be performed.
Patients with confirmed BIA-ALCL should undergo implant removal and removal of the surrounding scar capsule. This is a more extensive operation than implant removal alone.
As with any implanted device, it is good to keep a record of the device manufacturer, unique device identifier and implant model name. If you would like to obtain this information, a record of your surgery (operative notes) can be requested from the facility where your surgery took place.
Most cases of BIA-ALCL occur many years after breast implant placement. Further information can be found on the BAAPS website.
Mr Nduka is happy to see or speak to any patient who has concerns. Please email the office at firstname.lastname@example.org and someone will contact you to schedule an appointment.